Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
about
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control studyComparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived areaFunctional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat modelFolate: a key to optimizing health and reducing disease risk in the elderlyEffects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis.Mechanisms of membrane transport of folates into cells and across epithelia.Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity.Inflammation-mediated rheumatic diseases and atherosclerosisEndothelial dysfunction in young patients with rheumatoid arthritis and low disease activity.Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR geneDisease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.Pharmacogenetics of methotrexate.Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients.A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Serum homocystein level in patients with scleroderma.Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.Gene polymorphisms and pharmacogenetics in rheumatoid arthritisEffects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study.A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.Pharmacogenetics: implications for therapy in rheumatic diseases.Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis.Current concepts in the genetic diagnostics of rheumatoid arthritis.The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms.Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis.Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis.The C677T polymorphism in theMTHFRgene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population
P2860
Q24812262-1485CF91-05C4-4151-A71E-5A27AC709CA4Q28364851-4C9D4662-260F-417D-9F4B-99E570C22C1FQ28576740-C0BAAA4A-15A9-4EC6-BC51-8ADF973A40EDQ28645810-B94E7653-F1B1-4F34-B137-522C110645B7Q33395136-97168114-4A71-447D-AEA3-19DB1BB599BFQ33923484-825BD66F-220B-4F7D-911E-016600817077Q34184787-83E96171-54FE-4490-8CDB-C12ACB1ACA33Q34601733-C5EBE08C-451E-4DF4-A0D0-C539EC2C0BA4Q35024962-77F8415C-A74C-457C-AC06-A7BAFAC1F26CQ35480214-D4BF67AE-8D85-4254-8879-6E475463AF76Q35549285-B75D05B8-2908-4030-8CFF-8B799E76F3A2Q35553196-F43CA223-F01E-4FC1-8335-31129BF36C79Q35553306-A43F8E66-3DD9-4AFA-9DA8-3597CBFB2E2FQ35605663-56B12318-6B78-4953-9AE0-251530F12D57Q35911142-AB9ADBC8-8D89-49E5-9573-41526C9A5B7DQ36027291-3E5ED119-3FAB-4168-BA20-D03131DBF5BFQ36200678-C394C36A-E99C-4EC8-A817-0C5F4B295F29Q36660923-DAC8CB11-920E-4C3C-9740-8B635A1BC85DQ37058791-9103AD24-DB75-4AEB-89FB-5AD790FEC06DQ37214931-3040A2A6-5064-462A-B472-E9BCDBE22F93Q37267458-BCC9E6EF-08E6-4954-8F2F-AB0EA8C97049Q37633796-BCD834BF-D1AD-4BFC-AAA9-05EFC19AA341Q37913989-290BD716-9B9C-49D3-978F-36BD169D2B0CQ37946958-B3AA2098-6C60-4070-B0D0-E2175F1D26C2Q38238947-68E7E351-6EEB-4339-858B-B10B90E35C17Q40525673-C5439B04-3649-40C7-AF53-CF85E22A2D6CQ42970803-954AFA88-CE39-4737-99F6-100CB71BD5F2Q43800679-BF1ACEB6-FB2A-46F1-94FA-111EC6B354EDQ44016937-FA7DF2F2-A215-462D-BEA6-0B242802CA06Q44539907-488F3A7B-207D-4FF2-96ED-2026EA8792F5Q44621683-DA998335-56DB-440C-AF2D-52E007B135C7Q44948330-F6FC43E9-4720-4F1A-B4B9-82F65649A01BQ45939299-3D01FF05-CA0B-46BA-9459-7793FB1539ACQ46090014-1CD0D810-7FA3-42E5-988B-0746A0E97C05Q46249991-3582A78C-4FE7-4B1B-A8B2-940B2E6AD21BQ49680083-82575146-F117-4F80-AA7C-154EB93ED833Q50701881-FDB27531-EDEE-4250-8B10-120924905BF9Q53414640-2A281032-80BE-4FC5-9796-7340AA53111DQ58912366-2EE4ECBC-E6A6-49E4-8F04-EAD24BB9DCE0
P2860
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@ast
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@en
type
label
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@ast
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@en
prefLabel
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@ast
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@en
P2093
P2860
P356
P1476
Influence of sulphasalazine, m ...... ents with rheumatoid arthritis
@en
P2093
Giesendorf BA
Haagsma CJ
van Oppenraaij-Emmerzaal D
van Riel PL
van de Putte LB
van't Hof MA
P2860
P356
10.1136/ARD.58.2.79
P407
P577
1999-02-01T00:00:00Z